ResearchInvestigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design
ResearchiCARDIO Alliance global implementation guidelines for the management of obesity 2025 focus on prevention and treatment of cardiometabolic disease
ResearchiCARDIO Alliance Global Implementation Guidelines for the Management of Obesity: Focus on Prevention and Treatment of Cardiometabolic Disease
ResearchEarly Hemodynamic Safety of Simultaneous Initiation of Finerenone and Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes: The CONFIDENCE Trial
ResearchAcute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone
Jun 5, 2026Journal ArticleSafety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure.Written by 1 Roon author & 16 others Via The American Heart Association Journals
ResearchImpact of Simultaneous Initiation of Finerenone and Empagliflozin on Albuminuria Irrespective of Baseline HbA1c Levels in CKD and Type 2 Diabetes (CONFIDENCE Trial)
ResearchPotential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE-O Trial
ResearchGlycaemic Control According to the Final Insulin Dose Using an Innovative Fixed-Dose Titration of Weekly Insulin Efsitora in Insulin-Naive Type 2 Diabetes
ResearchSimplified Switching to Once-Weekly Insulin Icodec Without an Initial One-Time Additional Dose Versus Once-Daily Insulin Glargine U100 in Basal Insulin-Treated Type 2 Diabetes (ONWARDS 10): A Randomised Controlled Trial
ResearchEfficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a double-blind, randomised, active-controlled, phase 3 trial
ResearchElecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a randomised, double-blind, placebo-controlled phase 2 trial
ResearchElecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a randomised, double-blind, dose-finding, placebo-controlled trial
ResearchOral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial